Survival for patients with chronic myeloid leukaemia has improved but a proportion fail therapy. Failure is related to poorly defined genetic
abnormalities that may already be present at diagnosis. We will detect these abnormalities using state-of-the art sequencing technologies.
Our aim is to develop new ways to stratify patients at diagnosis according to their risk of treatment failure. These patients may receive more potent
drugs to reduce the risk of treatment failure and death.